Durect Corp (DRRX)

$0.8712

-0.04

(-4.26%)▲

Market is closed - opens 7 PM, 22 Apr 2024

Insights on Durect Corp

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 1.74M → 2.66M (in $), with an average increase of 34.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -12.22M → -1.44M (in $), with an average increase of 129.8% per quarter

  • Vs CTLT

    In the last 1 year, Catalent, Inc. has given 29.6% return, outperforming this stock by 110.1%

  • Vs NBIX

    In the last 3 years, Durect Corp has experienced a drawdown of -94.5%, however Neurocrine Biosciences Inc. resisted the overall trend and outperformed by 45.9%

Performance

  • $0.85
    $0.94
    $0.87
    downward going graph

    2.3%

    Downside

    Day's Volatility :9.33%

    Upside

    7.2%

    downward going graph
  • $0.47
    $7.46
    $0.87
    downward going graph

    45.94%

    Downside

    52 Weeks Volatility :93.7%

    Upside

    88.34%

    downward going graph

Returns

PeriodDurect CorpRussel 2000Index (Russel 2000)
3 Months
24.3%
0.0%
0.0%
6 Months
-68.84%
0.0%
0.0%
1 Year
-80.51%
-1.7%
-1.7%
3 Years
-94.45%
-20.7%
-20.7%

Highlights

Market Capitalization
28.2M
Book Value
$0.49
Earnings Per Share (EPS)
-1.2
PEG Ratio
-0.46
Wall Street Target Price
6.75
Profit Margin
0.0%
Operating Margin TTM
-234.32%
Return On Assets TTM
-43.79%
Return On Equity TTM
-138.93%
Revenue TTM
8.5M
Revenue Per Share TTM
0.33
Quarterly Revenue Growth YOY
-19.5%
Gross Profit TTM
16.5M
EBITDA
-36.9M
Diluted Eps TTM
-1.2
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.08
EPS Estimate Next Year
-1.23
EPS Estimate Current Quarter
-0.33
EPS Estimate Next Quarter
-0.28

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Durect Corp(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 674.79%

Current $0.87
Target $6.75

Company Financials

FY18Y/Y Change
Revenue
18.6M
↓ 62.25%
Net Income
-25.3M
↑ 585.3%
Net Profit Margin
-136.4%
↓ 128.89%
FY19Y/Y Change
Revenue
29.6M
↑ 59.25%
Net Income
-22.8M
↓ 10.01%
Net Profit Margin
-77.08%
↑ 59.32%
FY20Y/Y Change
Revenue
30.1M
↑ 1.85%
Net Income
-2.5M
↓ 88.93%
Net Profit Margin
-8.38%
↑ 68.7%
FY21Y/Y Change
Revenue
14.0M
↓ 53.58%
Net Income
-38.1M
↑ 1411.7%
Net Profit Margin
-272.77%
↓ 264.39%
FY22Y/Y Change
Revenue
19.3M
↑ 37.96%
Net Income
-35.6M
↓ 6.66%
Net Profit Margin
-184.54%
↑ 88.23%
FY23Y/Y Change
Revenue
8.5M
↓ 55.67%
Net Income
-27.6M
↓ 22.37%
Net Profit Margin
-323.16%
↓ 138.62%
Q3 FY22Q/Q Change
Revenue
12.0M
↑ 476.93%
Net Income
-2.8M
↓ 76.61%
Net Profit Margin
-23.46%
↑ 555.35%
Q4 FY22Q/Q Change
Revenue
3.3M
↓ 72.32%
Net Income
-9.4M
↑ 235.94%
Net Profit Margin
-284.77%
↓ 261.31%
Q1 FY23Q/Q Change
Revenue
2.1M
↓ 38.04%
Net Income
-12.2M
↑ 29.51%
Net Profit Margin
-595.23%
↓ 310.46%
Q2 FY23Q/Q Change
Revenue
2.1M
↑ 1.31%
Net Income
-11.2M
↓ 8.55%
Net Profit Margin
-537.29%
↑ 57.94%
Q3 FY23Q/Q Change
Revenue
1.7M
↓ 16.19%
Net Income
-3.0M
↓ 73.03%
Net Profit Margin
-172.88%
↑ 364.41%
Q4 FY23Q/Q Change
Revenue
2.7M
↑ 53.04%
Net Income
-1.4M
↓ 52.21%
Net Profit Margin
-53.99%
↑ 118.89%
FY18Y/Y Change
Total Assets
50.0M
↓ 5.86%
Total Liabilities
30.0M
↓ 5.14%
FY19Y/Y Change
Total Assets
86.0M
↑ 72.04%
Total Liabilities
63.2M
↑ 110.54%
FY20Y/Y Change
Total Assets
75.6M
↓ 12.07%
Total Liabilities
35.5M
↓ 43.75%
FY21Y/Y Change
Total Assets
92.0M
↑ 21.61%
Total Liabilities
34.2M
↓ 3.71%
FY22Y/Y Change
Total Assets
60.1M
↓ 34.67%
Total Liabilities
35.1M
↑ 2.65%
FY23Y/Y Change
Total Assets
45.2M
↓ 24.81%
Total Liabilities
30.4M
↓ 13.41%
Q3 FY22Q/Q Change
Total Assets
68.5M
↓ 2.15%
Total Liabilities
33.6M
↑ 1.03%
Q4 FY22Q/Q Change
Total Assets
60.1M
↓ 12.23%
Total Liabilities
35.1M
↑ 4.45%
Q1 FY23Q/Q Change
Total Assets
58.3M
↓ 2.91%
Total Liabilities
43.0M
↑ 22.47%
Q2 FY23Q/Q Change
Total Assets
48.7M
↓ 16.61%
Total Liabilities
43.2M
↑ 0.35%
Q3 FY23Q/Q Change
Total Assets
54.7M
↑ 12.48%
Total Liabilities
40.3M
↓ 6.57%
Q4 FY23Q/Q Change
Total Assets
45.2M
↓ 17.43%
Total Liabilities
30.4M
↓ 24.59%
FY18Y/Y Change
Operating Cash Flow
-19.8M
↑ 1370.59%
Investing Cash Flow
4.5M
↓ 64.25%
Financing Cash Flow
17.5M
↑ 38.48%
FY19Y/Y Change
Operating Cash Flow
11.1M
↓ 156.21%
Investing Cash Flow
-27.3M
↓ 702.25%
Financing Cash Flow
19.5M
↑ 11.56%
FY20Y/Y Change
Operating Cash Flow
-38.7M
↓ 448.65%
Investing Cash Flow
9.4M
↓ 134.52%
Financing Cash Flow
15.7M
↓ 19.7%
FY21Y/Y Change
Operating Cash Flow
-37.3M
↓ 3.6%
Investing Cash Flow
15.3M
↑ 62.33%
Financing Cash Flow
50.5M
↑ 222.68%
FY22Y/Y Change
Operating Cash Flow
-26.3M
↓ 29.57%
Investing Cash Flow
19.8M
↑ 29.55%
Financing Cash Flow
83.0K
↓ 99.84%
Q3 FY22Q/Q Change
Operating Cash Flow
-2.2M
↓ 77.89%
Investing Cash Flow
5.5M
↓ 29.51%
Financing Cash Flow
25.0K
↓ 3.85%
Q4 FY22Q/Q Change
Operating Cash Flow
-8.4M
↑ 277.34%
Investing Cash Flow
1.5M
↓ 72.98%
Financing Cash Flow
24.0K
↓ 4.0%
Q1 FY23Q/Q Change
Operating Cash Flow
-9.3M
↑ 10.13%
Investing Cash Flow
-4.9M
↓ 433.6%
Financing Cash Flow
10.0M
↑ 41566.67%
Q2 FY23Q/Q Change
Operating Cash Flow
-9.3M
↑ 0.86%
Investing Cash Flow
1.8M
↓ 137.39%
Financing Cash Flow
-34.0K
↓ 100.34%

Technicals Summary

Sell

Neutral

Buy

Durect Corp is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Durect Corp
Durect Corp
-22.88%
-68.84%
-80.51%
-94.45%
-83.91%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-5.91%
19.27%
26.39%
39.74%
65.51%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-2.98%
-1.09%
-6.87%
9.72%
9.72%
Zoetis Inc.
Zoetis Inc.
-11.48%
-8.88%
-12.5%
-8.92%
52.93%
Viatris Inc.
Viatris Inc.
-6.32%
19.44%
13.12%
-16.08%
-31.95%
Catalent, Inc.
Catalent, Inc.
-0.27%
29.35%
29.56%
-48.63%
26.7%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Durect Corp
Durect Corp
NA
NA
-0.46
-1.08
-1.39
-0.44
NA
0.49
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
53.66
53.66
0.44
4.78
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.96
28.96
1.69
0.45
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
30.2
30.2
2.58
5.8
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
222.0
222.0
NA
2.78
0.0
0.03
0.04
17.05
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.48
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Durect Corp
Durect Corp
Buy
$28.2M
-83.91%
NA
0.0%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$13.3B
65.51%
53.66
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$37.0B
9.72%
28.96
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$70.0B
52.93%
30.2
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.2B
-31.95%
222.0
0.35%
Catalent, Inc.
Catalent, Inc.
Hold
$10.1B
26.7%
211.02
-31.77%

Institutional Holdings

  • Ingalls & Snyder LLC

    7.19%

  • Vanguard Group Inc

    3.60%

  • Richmond Brothers Inc

    1.74%

  • Gagnon Securities LLC

    1.20%

  • BlackRock Inc

    1.14%

  • Beirne Wealth Consulting Services, LLC

    1.07%

Corporate Announcements

  • Durect Corp Earnings

    Durect Corp’s price-to-earnings ratio stands at None

    Read More

Company Information

durect is a specialty pharmaceuticals company with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain management, acute organ injury and metabolic diseases. durect’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. late stage development programs of this nature include remoxy® and posidur™. durect’s epigenomic regulator program includes the lead molecule dur-928 in phase 1 clinical testing. dur-928 is an endogenous small molecule that is an epigenomic modulator of cellular activities involved in lipid homeostasis, metabolic disease, inflammation and cell survival. for more information, please visit www.durect.com. we also manufacture and sell two commercial product lines: • alzet® osmotic pumps use

Organization
Durect Corp
Employees
58
CEO
Dr. James E. Brown D.V.M.
Industry
Health Technology

Discover More

FAQs